AB 公司 Clarion 1.2 型人工耳蜗植入体翻修术后的效果。
Outcomes after revision of Advanced Bionics Clarion 1.2 cochlear implants.
机构信息
Department of Otolaryngology-Head and Neck Surgery and Cochlear Implant Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
Cochlear Implants Int. 2023 Jul;24(4):190-194. doi: 10.1080/14670100.2023.2198789. Epub 2023 Apr 24.
INTRODUCTION
Cochlear implant reimplantation (CIR) for external processor upgrade or device failure is becoming increasingly common as the population of cochlear implant recipients ages. Patients with Advanced Bionics (AB) Clarion 1.2 cochlear implants may undergo CIR for device age/failure or desired technology upgrade so that they may use newer external processors that have improved connectivity features. The objective of this study was to evaluate audiologic outcomes for patients who were initially implanted with an AB Clarion 1.2 internal device and underwent CIR for technology upgrade or device failure.
METHODS
Retrospective chart review was performed at a single academic medical center for patients (pediatric and adult) with an AB Clarion 1.2 internal device who underwent CIR to a later generation AB internal device and had available audiologic data.
RESULTS
Forty-eight individuals with a Clarion 1.2 implant underwent CIR. Pre- and post-CIR speech understanding did not change for AzBio (p-value = 0.11, mean change = 12.1%, 95% CI = -2.9-27.2%), CNCw (p-value = 0.74, mean change = -1%, 95% CI = -10.4-12.4%), or HINT (p-value = 0.12, mean change = 19.9%, 95% CI = -2.6-42.4%) scores. Pure-tone averages improved following CIR (p-value < 0.01, mean change = 4.3 dB, 95% CI = 1.5-7.1 dB).
CONCLUSIONS
Revision of AB Clarion 1.2 cochlear implants does not significantly worsen audiologic outcomes and may improve hearing in some individuals, but individual patient-level outcomes are variable.
引言
随着接受耳蜗植入的人群年龄的增长，外部处理器升级或设备故障的耳蜗植入再植入（CIR）变得越来越常见。使用 Advanced Bionics（AB）Clarion 1.2 耳蜗植入物的患者可能会因设备老化/故障或所需技术升级而进行 CIR，以便他们可以使用具有改进连接功能的新型外部处理器。本研究的目的是评估最初植入 AB Clarion 1.2 内部设备并因技术升级或设备故障而接受 CIR 的患者的听力结果。
方法
在一家学术医疗中心对接受 AB Clarion 1.2 内部设备 CIR 以更新代 AB 内部设备的患者（儿科和成人）进行了回顾性图表审查，并获得了可用的听力数据。
结果
48 名 Clarion 1.2 植入物患者接受了 CIR。在 AzBio（p 值 = 0.11，平均变化 = 12.1%，95%CI = -2.9-27.2%）、CNCw（p 值 = 0.74，平均变化 = -1%，95%CI = -10.4-12.4%）或 HINT（p 值 = 0.12，平均变化 = 19.9%，95%CI = -2.6-42.4%）评分方面，CIR 前后的言语理解能力并未改变。CIR 后纯音平均值得到改善（p 值 < 0.01，平均变化 = 4.3 dB，95%CI = 1.5-7.1 dB）。
结论
AB Clarion 1.2 耳蜗植入物的修正并不会显著恶化听力结果，并且在某些个体中可能会改善听力，但个体患者的结果是可变的。
Zotero 插件